- Jeb Bush: Trump is ‘a distraction in and of himself’ March 27, 2017
- 'Dreamer' immigrant in Oregon detained by US authorities March 26, 2017
- A Life-Threatening Disease Destroyed Her Nose March 27, 2017
- Tesaro Announces FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer March 27, 2017
- The coincidences mount, as another Putin critic is shot dead March 24, 2017
- FDA Approves Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation March 23, 2017
- FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma March 23, 2017
- FDA Approves Xadago (safinamide) as an Add-On Treatment for Patients with Parkinson’s Disease March 21, 2017
- FDA Approves Juvéderm Vollure XC for Correction of Facial Wrinkles and Folds in Adults March 20, 2017
- Meals on Wheels receives massive donations following proposed budget cut. Will it matter? March 19, 2017
Bactroban is the brand name of mupirocin, an antibacterial agent, as originally manufactured by GlaxoSmithKline. It is now available as a generic preparation from Ortho McNeil Pharmaceutical Inc called Centany or Teva called Mupirocin.
Mupirocin ointment is marketed as Bactroban Calcium Cream 2% containing the dihydrate crystalline calcium hemi-salt of the antibiotic mupirocin. It comes from the fermentation of Pseudomonas fluorescens and is effective against gram-positive bacteria including Staphylococcus aureus (MRSA) and Streptococcus pyogenes as well as some gram-negative bacteria. Mupirocin acts by inhibiting the synthesis of bacterial protein by binding to the bacterial isoleucyl transfer-RNA synthetase and has been found to have no risk of cross-resistance with other antimicrobial agents. Prolonged use, however, increases the risks of developing resistance to the antibiotic as well as secondary infections from
non-bacterial agents such as fungi.
Bactroban Cream is applied topically to open wounds and impetigo, a skin infection, but is not recommended for use on mucosal surfaces, such as the eyes. The Food and Drug Administration has classified the antibacterial agent as Pregnancy Category B, indicating that there appears to be no harmful effects on its use by pregnant women. However, it is recommended that it only be used if there is no choice. The same applies to nursing mothers. Bactroban Cream has been approved for the use of children from 3 months to 16 years. In case of an allergic reaction, discontinue use immediately.
Some side effects associated with the use of Bactroban Cream may include:
• abdominal pain
• burning sensation
• ulcerative stomatitis
• secondary wound infection and dizziness
Clinical studies place the occurrences of some of these side effects at 8.3% of the study population at most.
Bactroban Cream should be used in accordance with the doctor’s instructions and should be used for the full course of treatment for maximum benefit. It should not be used for longer than prescribed, however, and if the condition appears to worsen after three days of use the doctor should be informed of this at once. There are no known food and drug interactions with Bactroban.
Aside from Bactroban Calcium Cream 2%, the preparation is available as Bactroban Ointment 2% and Bactroban Nasal Ointment 2%. Bactroban Nasal is used for the prevention of S. aureus colonization in adult patients and health workers who may be exposed on an institutional basis to the bacteria. It is applied in the nostrils for